摘要
目的:对我院93例结直肠癌患者4种化疗方案化疗后骨髓抑制发生情况进行回顾分析,为临床安全用药提供参考。方法:收集整理我院2014年4月~2015年3月共93例结直肠癌患者化疗后的骨髓抑制发生情况,根据患者情况及化疗方案分析其发生特点及影响因素。结果:93例结直肠患者经化疗后,发生骨髓抑制39例(41.94%),其中重度骨髓抑制为7例(17.95%);骨髓抑制发生时间主要集中在化疗后1~2周内;不同性别、年龄患者骨髓抑制构成比差异无统计学意义;多药联合化疗所致的骨髓抑制发生率(50%)较单药(27.27%)高,差异有统计学意义(P<0.05)。结论:化疗方案与患者发生骨髓抑制概率密切相关。因此,临床医生与药师应慎重选择化疗方案,密切监测骨髓抑制发生时间,采取积极措施降低骨髓抑制的发生风险,促进患者用药安全。
Objective：In our hospital 93 cases of colorectal cancer patients with four chemotherapy regimens hap- pened bone marrow depression after chemotherapy were analyzed, and provide reference for clinical medication safety. Methods：Collected from April 2014 to March 2015 a total of 93 cases of colorectal cancer after chemotherapy in patients with bone marrow suppression, according to the situation of patients and chemotherapy regimens to analyze its characteris- tics and influence factors. Results：93 patients with colorectal after chemotherapy, bone marrow depression of 39 cases （41.94%）, severe bone marrow depression of the 7 cases （ 17.95% ）. Bone marrow depression occurred mainly in 1 to 2 weeks after chemotherapy. There was no statistically significant difference incidence of bone marrow depression with gender and age. The incidence of bone marrow depression caused by multi-drug combination chemotherapy is higher than single-a- gent chemotherapy. The difference was statistically significant （ P 〈 0.05 ）. Conclusion： Chemotherapy regimens was close- ly related to the probability of bone marrow depression in patients. Therefore, clinical doctors and pharmacists should care- fully choose chemotherapy regimens, close monitoring of bone marrow depression occurred, to take active measures to re- duce the risk of bone marrow depression, promote patients medication safety.
出处
《药物流行病学杂志》
CAS
2017年第9期631-634,共4页
Chinese Journal of Pharmacoepidemiology
基金
德阳市2014年度应用技术研究与开发资金计划项目(编号:2014SZ097-2)
关键词
结直肠癌
化疗
骨髓抑制
Colorectal cancer
Chemotherapy
Bone marrow depression
